Effect of Moxibustion on the Serum Levels of MMP‐1, MMP‐3, and VEGF in Patients with Rheumatoid Arthritis

Zeyun Yu, Yingni Wang, Yuan Li, Chenxi Liao, Jingyang Dai, Yun Luo, Yuanzhang Hu, Siyu Tao, Jie Tang, Guanhua Chen, Ping WuEvidence-based 2020 · DOI

TL;DR

This study investigates the therapeutic effects of moxibustion, a traditional Chinese medicine technique, on rheumatoid arthritis (RA). Researchers found that moxibustion, when combined with conventional treatment, significantly improved clinical symptoms and reduced key inflammatory and tissue-degrading markers (IL-1β, TNF-α, MMP-1, MMP-3, and VEGF) in RA patients, suggesting a potential role in bone protection.

What Problem Does This Paper Address?

Rheumatoid arthritis (RA) is a chronic, autoimmune disease that leads to progressive joint damage, deformity, and functional loss. While conventional treatments exist, they often come with significant side effects and may not fully halt disease progression. There's a need for effective, complementary therapies that can alleviate RA symptoms and potentially protect joint structures. Specifically, this paper addresses the need to understand the underlying mechanisms by which moxibustion, a heat-based therapy, might exert its beneficial effects in RA patients, focusing on its impact on specific biomarkers related to inflammation and tissue degradation.

Methods

The study employed a randomized controlled trial design. Seventy RA patients were recruited and randomly assigned to either a treatment group (conventional medicine + moxibustion) or a control group (conventional medicine only). Both groups received standard RA medications (methotrexate, folate, or leflunomide). The treatment group additionally received moxibustion at specific acupoints (ST36, BL23, and Ashi points) twice a week for four weeks, repeated for two courses.

Key outcome measures included:

  • Clinical Symptoms: Assessed using morning stiffness scores, tenderness index, swelling index, visual analog scale (VAS) for pain, and disease activity score of 28 joints (DAS28).
  • RA Serological Disease Markers: Rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
  • Inflammatory Factors and Bone Metabolic Indexes: Serum levels of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-3 (MMP-3), and vascular endothelial growth factor (VEGF).

Serum samples were collected before and after the 8-week treatment period and analyzed using enzyme-linked immunosorbent assay (ELISA). Statistical analysis involved independent samples t-tests and Mann-Whitney U tests to compare groups.

Datasets

Not discussed in the paper. The study utilized patient data collected from the Hospital of Chengdu University of Traditional Chinese Medicine.

Key Insights and Ideas

  • Moxibustion Enhances Conventional Treatment: The combination of moxibustion with standard RA medications yielded significantly better improvements in clinical symptoms compared to conventional treatment alone.
  • Targeting Key Inflammatory Pathways: Moxibustion appears to reduce the levels of pro-inflammatory cytokines like IL-1β and TNF-α, which are known drivers of RA pathogenesis.
  • Inhibiting Tissue Degradation: A crucial finding is the significant reduction in MMP-1 and MMP-3 levels in the moxibustion group. These enzymes are critical for cartilage and bone breakdown in RA.
  • Modulating Angiogenesis: The observed decrease in VEGF levels in the treatment group suggests moxibustion may also help control the neovascularization that contributes to synovial inflammation and pannus formation in RA.
  • Potential for Bone Protection: By reducing MMP-1 and MMP-3, moxibustion may offer a protective effect against the bone erosion characteristic of RA.

Key Results

  • Clinical Symptoms: Both groups showed improvement in clinical symptoms (tenderness, swelling, stiffness, VAS, DAS28) after treatment (P < 0.01). However, the treatment group demonstrated significantly greater improvement compared to the control group (P < 0.05).
  • Serological Markers: While both groups showed improvement in ESR, CRP, and RF, intergroup comparisons did not reveal significant differences in the improvement of these markers.
  • Inflammatory Markers (IL-1β, TNF-α, VEGF): Levels of IL-1β and VEGF decreased in both groups after treatment (P < 0.01 for treatment, P < 0.05 for control). TNF-α also decreased (P < 0.05). Importantly, the treatment group showed significantly lower levels of IL-1β, TNF-α, and VEGF compared to the control group (P < 0.05).
  • Bone Metabolic Indexes (MMP-1, MMP-3): Significant differences in MMP-1 and MMP-3 levels were observed before and after treatment in the treatment group (P < 0.05). The changes in MMP-1 and MMP-3 were significantly better in the treatment group compared to the control group (P < 0.05).

Limitations and Future Work

  • Limited Impact on Serological Markers: The study noted no significant difference in the improvement of RA serological disease markers (ESR, CRP, RF) between the groups. The authors speculate this might be due to the chronic nature of RA and the relatively short treatment duration, suggesting that changes in these markers might take longer to become apparent.
  • Imaging for Bone Destruction: The authors acknowledge that while their study suggests a potential bone-protective effect, it did not include imaging examinations to confirm whether moxibustion can reverse or delay articular cartilage and bone destruction. They recommend future studies incorporate imaging data for a more comprehensive assessment.
  • Mechanism Complexity: The precise internal mechanism of moxibustion's action is complex and involves multiple pathways. While this study highlights key molecular targets, further research is needed to fully elucidate these intricate interactions.

Summary updated

Abstract

The improvement effect of moxibustion on the clinical symptoms of RA patients may be related to influence on the contents of IL-1<i>β</i>, TNF-<i>α</i>, MMP-1, MMP-3, and VEGF, and moxibustion may play a potential role in bone protection.
BibTeX
@inproceedings{yu2020effect,
  author = {Zeyun Yu and Yingni Wang and Yuan Li and Chenxi Liao and Jingyang Dai and Yun Luo and Yuanzhang Hu and Siyu Tao and Jie Tang and Guanhua Chen and Ping Wu},
  title = {{Effect of Moxibustion on the Serum Levels of MMP‐1, MMP‐3, and VEGF in Patients with Rheumatoid Arthritis}},
  booktitle = {Evidence-based},
  year = {2020},
  doi = {10.1155/2020/7150605},
}
Figure